407-22-7

Basic information

• Product Name: 2-Fluoro-6-methylpyridine
• Synonyms: 6-FLUORO-2-PICOLINE;2-FLUORO-6-METHYLPYRIDINE;2-FLUORO-6-PICOLINE;Pyridine, 2-fluoro-6-methyl-;2-FLUORO-6-METHYLPYRIDINE 98%;2-Fluoro-6-methylpyridine/2-Fluoro-6-Picoline;2-Fluoro-6-methylpyridine98%;6-methyl-2-fluoropyridine
• CAS NO: 407-22-7
• Molecular Formula: C₆H₆FN
• Molecular Weight: 111.12
• EINECS: 206-980-8
• Product Categories: Fluorin-contained pyridine series;Pyridine;Pyridines, Pyrimidines, Purines and Pteredines;Pyridines;Fluoropyridines;Halopyridines;Fluorine series
• Mol File: 407-22-7.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 140-141 °C(lit.)
• Flash Point: 152 °F
• Appearance: /
• Density: 1.077 g/mL at 25 °C(lit.)
• Vapor Pressure: 31.4mmHg at 25°C
• Refractive Index: n20/D 1.47(lit.)
• Storage Temp.: Keep in dark place,Sealed in dry,Room Temperature
• PKA: 0.29±0.10(Predicted)
• BRN: 107084
• CAS DataBase Reference: 2-Fluoro-6-methylpyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Fluoro-6-methylpyridine(407-22-7)
• EPA Substance Registry System: 2-Fluoro-6-methylpyridine(407-22-7)

Safety Data

• Hazard Codes: Xi,F
• Statements: 36/37/38
• Safety Statements: 26-36
• RIDADR: 1993
• WGK Germany: 3
• HazardClass: IRRITANT
• Hazardous Substances Data: 407-22-7(Hazardous Substances Data)

Usage

Description

2-Fluoro-6-methylpyridine, also known as 2-fluoro-6-picoline, is a liquid chemical compound that can be synthesized through the diazotization of 2-amino-6-methylpyridine in a hydrogen fluoride solution containing 40% pyridine. 2-Fluoro-6-methylpyridine has been studied for the effects of substituents on its spectral properties using 13C NMR, UV, and IR spectral data.

Uses

Used in Pharmaceutical Industry:
2-Fluoro-6-methylpyridine is used as a chemical intermediate for the synthesis of various pharmaceutical compounds, including:
1. 2-fluoro-6-pyridinecarboxylic acid, which may have potential applications in the development of new drugs targeting specific receptors or enzymes.
2. 2,2′-[1-(6-methylpyridin-2-yl)ethane-1,1-diyl]dipyridine, which could be utilized in the creation of novel molecules with potential therapeutic properties.
3. 2-fluoropyridine-6-aldoxime, a compound that may be further modified for use in medicinal chemistry.
4. 2-fluoro-6-(dibromomethyl)pyridine, which can be a starting point for the development of new chemical entities with specific biological activities.
The versatility of 2-fluoro-6-methylpyridine as a chemical intermediate makes it a valuable compound in the pharmaceutical industry for the development of new drugs and therapeutic agents.

InChI:InChI=1/C4H4F5I/c5-3(6,1-2-10)4(7,8)9/h1-2H2

Upstream product

• 1824-81-3 2-Amino-6-methylpyridine 
• 18368-63-3 6-chloro-2-picoline 

Downstream Products

• 402-69-7 6-fluoropyridine-2-carboxylic acid 
• 878744-13-9 2-methyl-2-(6-methylpyridin-2-yl)propanenitrile 
• 315180-16-6 6-(chloromethyl)-2-fluoropyridine 
• 5315-24-2 1-(6-methylpyridin-2-yl)hydrazine 
• 217657-76-6 6-(methylthio)pyridine-2-carboxaldehyde 

Relevant articles and documents

Targeting cyclic nucleotide phosphodiesterase 5 (PDE5) in brain: Toward the development of a PET radioligand labeled with fluorine-18

With the aim to develop a specific radioligand for imaging the cyclic nucleotide phosphodiesterase 5 (PDE5) in brain by positron emission tomography (PET), seven new fluorinated inhibitors (3–9) were synthesized on the basis of a quinoline core. The inhibitory activity for PDE5 together with a panel of other PDEs was determined in vitro and two derivatives were selected for IC50 value determination. The most promising compound 7 (IC50 = 5.92 nM for PDE5A), containing a 3-fluoroazetidine moiety, was further radiolabeled by aliphatic nucleophilic substitution of two different leaving groups (nosylate and tosylate) using [18F]fluoride. The use of the nosylate precursor and tetra-n-butyl ammonium [18F]fluoride ([18F]TBAF) in 3-methyl-3-pentanol combined with the addition of a small amount of water proved to be the best radiolabeling conditions achieving a RCY of 4.9 ± 1.5% in an automated procedure. Preliminary biological investigations in vitro and in vivo were performed to characterize this new PDE5 radioligand. Metabolism studies of [18F]7 in mice revealed a fast metabolic degradation with the formation of radiometabolites which have been detected in the brain.

Facile preparation of aromatic fluorides by deaminative fluorination of aminoarenes using hydrogen fluoride combined with bases

One-pot deaminative fluorination of aminoarenes including heteroaromatics, namely, diazotization of aminoarenes followed by in situ fluoro-dediazoniation of the corresponding diazonium ions, was successfully accomplished to produce fluoroarenes in high yields by using hydrogen fluoride combined with base solutions. The diazotization stage has been found to play the most important part in yielding fluoroarenes effectively. It was greatly influenced by the composition of the HF solution and enhanced by employing appropriate amounts of bases such as pyridine under carefully controlled conditions. The fluoro-dediazoniation stage was effectively accelerated photochemically to afford fluoroarenes having polar substituents such as hydroxyl, nitro and so on in high yields.

A Facile Preparation of Fluoropyridines from Aminopyridines via Diazotation and Fluorodediazoniation in HF or HF-Pyridine Solutions

Fluoropyridines were prepared in high yields by dizotation of aminopyridines in HF or HF-pyridine solutions, followed by dediazoniation in situ at 20-60 deg C.